|
[1]MCCONACHIE SM, WILHELM SM, KALEPRADHAN PB.New direct-acting antivirals in hepatitis C therapy:a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir[J].Expert Rev Clin Phar, 2016, 9 (2) :287-302.
|
|
[2]PENG HY, YANG EN, SUN DX.Research advances in sofosbuvir for treatment of chronic hepatitis C[J].J Clin Hepatol, 2016, 32 (4) :798-801. (in Chinese) 彭焕彦, 杨二娜, 孙殿兴.索非布韦治疗慢性丙型肝炎的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :798-801.
|
|
[3]ASSELAH T, BOYER N, SAADOUN D, et al.Direct-acting antivirals for the treatment of hepatitis C virus infection:optimizing current IFN-free treatment and future perspectives[J].Liver Int, 2016, 36 (Suppl 1) :47-57.
|
|
[4]LI Q, HUANG YX, CHEN L.Research progress of interferon free anti HCV regimen[J].J Clin Hepatol, 2016, 32 (1) :169-173. (in Chinese) 李强, 黄玉仙, 陈良.无干扰素抗HCV方案的研究进展[J].临床肝胆病杂志.2016, 32 (1) :169-173.
|
|
[5]HE YM, HOU B.PEG-IFNα-2a and ribavirin for decompensated cirrhotic patients with hepatitis C after eliminating complication[J].Chin J Med Offic, 2017, 45 (4) :397-400. (in Chinese) 何妍梅, 侯波.聚乙二醇干扰素啊α-2a联合利巴韦林治疗失代偿期丙肝肝硬化并发症消除后患者临床观察[J].临床军医杂志, 2017, 45 (4) :397-400.
|
|
[6]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatitis Cduring antiviral treatment[J].J Jilin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chinese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学学报:医学版, 2016, 42 (1) :99-103.
|
|
[7]CHANG CY, NGUYEN P, LE A, et al.Real-world experience with interferon-free, direct acting antiviral therapies in Asian A-mericans with chronic hepatitis C and advanced liver disease[J].Medicine, 2017, 96 (6) :e6128.
|
|
[8]RAO ZF, WANG WG, CHENG ZL, et al.Antiviral therapy for chronic hepatitis C complicated with cirrhosis[J].China Pharmacist, 2016, 19 (2) :357-359. (in Chinese) 饶志方, 王婉钢, 程振玲, 等.慢性丙型肝炎合并肝硬化的抗病毒方案[J].中国药师, 2016, 19 (2) :357-359.
|
|
[9]WANG YY, NIE QH.study of direct antiviral drugs and their treatment for chronic hepatitis C[J].Chin Hepatol, 2016, 21 (2) :140-142. (in Chinese) 王媛媛, 聂青和.直接抗病毒药物研究及其治疗慢性丙型肝炎现状[J].肝脏, 2016, 21 (2) :140-142.
|
|
[10]XIE Y.DAA era of antiviral therapy for chronic hepatic C and standard Peg IFN/RBV therapy in China[J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (3) :40-41. (in Chinese) 谢尧.中国慢性丙型肝炎抗病毒治疗DAA时代与Peg IFN/RBV标准治疗[J/CD].中国肝脏病杂志:电子版, 2015, 7 (3) :40-41.
|
|
[11]NAKAMURA M, KANDA T, HAGA Y, et al.Sofosbuvir treatment and hepatitis C virus infection[J].World J Hepatol, 2016, 8 (3) :183-190.
|
|
[12]LEE LY, TONG CYW, WONG T, et al.New therapies for chronic hepatitis C infection:a systematic review of evidence from clinical trials[J].Int J Clin Pract, 2012, 66 (4) :342.
|
|
[13]CHEN JH, XU XY.Study on the related variants of direct antiviral drugs in hepatitis C[J].Infect Dis Info, 2016, 29 (2) :116-120. (in Chinese) 陈建宏, 徐小元.丙型肝炎直接抗病毒药物耐药相关变异的研究[J].传染病信息, 2016, 29 (2) :116-120.
|
|
[14]PHILIPP S, HEINER W.The new era of interferon-free treatment of chronic hepatitis C[J].Viszeralmedizin, 2015, 31 (4) :290-296.
|
|
[15]BHATIA HK, SINGH H, GREWAL N, et al.Sofosbuvir:a novel treatment option for chronic hepatitis C infection[J].J Pharmacol Pharmacother, 2014, 5 (4) :278-284.
|
|
[16]GREIG SL.Sofosbuvir/velpatasvir:a review in chronic hepatitis C[J].Drugs, 2016, 76 (16) :1-12.
|
|
[17]HEZODE C, CHEVALIEZ S, SCOAZEC G, et al.Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen[J].Hepatology, 2016, 63 (6) :1809.
|
|
[18]BANERJEE D, REDDY KR.Review article:safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis Ctherapy[J].Aliment Pharmacol Ther, 2016, 43 (6) :674-696.
|
|
[19]ELBAZ T, ELKASSAS M, ESMAT G.New era for management of chronic hepatitis C virus using direct antiviral agents:a review[J].J Adv Res, 2015, 6 (3) :301-310.
|
|
[20]ZHOU SN, ZHANG M.Metabolism and drug interaction of hepatitis C direct antiviral drugs[J].Infect Dis Info, 2016, 29 (2) :121-125. (in Chinese) 周双男, 张敏.丙型肝炎直接抗病毒药物的代谢及药物相互作用[J].传染病信息, 2016, 29 (2) :121-125.
|
|
[21]GRITSENKO D, HUGHES G.Ledipasvir/sofosbuvir (harvoni) :improving options for hepatitis C virus infection[J].P T, 2015, 40 (4) :256-576.
|
|
[22]MANNS M, POL S, JACOBSON IM, et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational, phase 3, multicohort study[J].Lancet, 2014, 384 (9954) :1597-1605.
|
|
[23]MORIO K, IMAMURA M, KAWAKAMI Y, et al.Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients[J].J Gastroenterol Hepatol, 2016, 32 (3) :645-650.
|
|
[24]SARRAZIN C.The importance of resistance to direct antiviral drugs in HCV infection in clinical practice[J].J Hepatol, 2016, 64 (2) :486-504.
|
|
[25]MCPHEE F, FRIBORG J, LEVINE S, et al.Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir[J].Antimicrob Agents Chemother, 2012, 56 (7) :3670-3681.
|
|
[26]LONTOK E, HARRINGTON P, HOWE A, et al.Hepatitis C virus drug resistance-associated substitutions:state of the art summary[J].Hepatology, 2015, 62 (5) :1623-1632.
|
|
[27]OGAWA E, FURUSYO N, NOMYRA H, et al.Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65and over with or without cirrhosis[J].Antiviral Res, 2016, 136:37-44.
|
|
[28]KOZUKA R, HAI H, TERANISHI Y, et al.ITPA polymorphism correlates with the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy[J].J Gastroenterol Hepatol, 2017, 32 (8) :1495-1502.
|
|
[29]ANNAROSA, FLOREANI.Hepatitis C and pregnancy[J].World JGastroenterol, 2013, 19 (40) :6714-6720.
|
|
[30]AFDHAL N, ZEUZEM S, KWO P, et al.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med, 2014, 370 (16) :1483-1493.
|
|
[31]OYA Y, SUGAWARA Y, WATANABE T, et al.Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation[J].Biosci Trends, 2017, 10 (6) :496-499.
|
|
[32]KOWDLEY KV, GORDON SC, REDDY KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med, 2014, 370 (20) :1879-1888.
|
|
[33]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection[G].World Health Organization, 2016:1-133.
|
|
[34]GAMAL N, GITTO S, ANDREONE P.Efficacy and safety of daclatasvir in hepatitis C:an overview[J].J Clin Transl Hepatol, 2016, 4 (4) :336-344.
|
|
[35]KARINO Y, TOYOTA J, IKEDA K, et al.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.[J].JHepatol, 2013, 58 (4) :646-654.
|
|
[36]UCHIDA Y, KOUYAMA JI, NAIKI K, et al.Development of rare RAVs that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism[J].Hepatol Res, 2016, 46 (12) :1234-1246.
|
|
[37]LAWITZ E, SULKOWSK MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.
|
|
[38]CHAN HL, TSANG OT, HUI YT, et al.Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir in chronic hepatitis C patients in Hong Kong[J].J Gastroenterol Hepatol, 2017, 32 (6) :1230-1233.
|
|
[39]EVERSON GT, TOWNER WJ, DAVIS MN, et al.Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1to 6 hepatitis C virus infection:a randomized trial[J].Ann Intern Med, 2015, 163 (11) :818-826.
|
|
[40]FELD JJ, JACOBSON IM, HEZODE C, et al.Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection[J].N Engl J Med, 2015, 373 (27) :2599.
|
|
[41]LAWITZ E, POORDAD F, WELLS J, et al.Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV[J].Hepatology, 2017, 65 (6) :1803-1809.
|
DownLoad: